• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Philips, Illumina partner on integrated genomics solutions for oncology

Philips, Illumina partner on integrated genomics solutions for oncology

January 9, 2017
CenterWatch Staff

Royal Philips, a global leader in health technology, and Illumina, a global leader in DNA sequencing and array-based technologies, has announced a strategic collaboration that aims to integrate Illumina's sequencing systems for large-scale analysis of genetic variation and function and Philips' IntelliSpace Genomics clinical informatics platform, and to coordinate marketing and sales of the resulting solutions. Philips and Illumina will also seek to engage in clinical research collaborations with health systems in the U.S. that want to develop precision medicine programs in oncology.

Profiling tumors using genomic information is critical for complex cancer cases, and next-generation DNA sequencing—the process of rapidly profiling large sections of the genome in parallel to find mutations—is increasingly being used for this. However, challenges remain in developing ways to rapidly and accurately interpret genomic findings in the context of a patient's condition. While cancer patients can have hundreds of gene variants in their tumors, only a small number may actually drive the individual's specific cancer or may have actionable therapeutic implications for a particular patient. The patient's history, related lab tests and cancer type are needed for a meaningful interpretation of the genomic data.

Philips and Illumina will collaborate to provide new solutions aimed at the acquisition, analysis, annotation and interpretation of genomics data in oncology cases. The data will be acquired by Illumina's BaseSpace Sequence Hub connected to its instruments and will be processed through Philips' IntelliSpace Genomics solution for oncology. This solution will combine data from multiple sources—radiology, immunohistochemistry, digital pathology, medical records and lab tests—and will deliver a consolidated dashboard view. This system will support researchers to develop insights more efficiently and will ultimately support lowering the cost of health care delivery and improved health outcomes.

"The value of genomic information for personalized care, and for the treatment of patients with cancer in particular, is tremendous," said Jeroen Tas, CEO of Connected Care and Health Informatics at Philips. "Until now the ability to use genomic data with the aim of having a precise diagnosis of cancer and improve treatment was mostly for the domain of academic centers. Through this collaboration we will unlock the value of genomics for a much wider group of laboratories and care providers to help them advance genomics initiatives at greater speed with the aim to offer precision medicine with better outcomes for their patients."

"We believe that this collaboration will provide an excellent path for our next-generation sequencing systems to be incorporated into health systems in the U.S. and worldwide," said Francis deSouza, president and CEO of Illumina. "One key strategy in our commitment to improving human health is connecting genomics to the everyday business of healthcare: based on integrated patient data, embedded into clinical pathways, supported by real-world evidence and reimbursement models."

The two companies intend to collaborate on system integration, cohort analysis and health economics applications, and future research programs. Laboratories adopting the solution will be able to integrate sequencing data with information from multiple data sources (e.g., imaging, pathology and laboratory). The Illumina-Philips solution will also give them ready access to advanced analytics, deep learning technologies and available reference literature, guidelines, and evidence in a single view.

IntelliSpace Genomics is powered by Philips HealthSuite, a secure, cloud-enabled ecosystem of systems, clinical applications and digital tools that gives access to advanced capabilities such as universal big data management, predictive analytics, artificial intelligence and Internet of Things (IoT) to support clinicians in first-time-right decision support. This enables Philips IntelliSpace Genomics to deliver real-time, actionable information to physicians and specialists for therapy planning, across locations.

BaseSpace Sequence Hub is a cloud-based platform that seamlessly extends Illumina instruments for the acquisition and analysis of genomic data, and managing sequencing runs and Illumina sequencing platforms to optimize operations. It enables the sharing of genomic data with a broad range of value-added Illumina and ecosystem analysis applications.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing